Revenue segments as reported by the company.

Net product sales

Alliance and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, selling and administrative

Research and development

IPRD charge - MyoKardia acquisition

Amortization of acquired intangible assets

Other (income)/ expense, net

Acquired IPRD

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bristol-Myers

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bristol-Myers reports robust 2022 performance and outlines growth strategies

Bristol-Myers Squibb delivered strong financial performance in 2022, with revenue growth and key product successes driving sales to $46 billion.
The company's strategic focus on portfolio expansion, market access enhancement, and operational efficiency positions it for continued growth and value creation.
Challenges around market access, legislative impacts, and expense management require strategic attention, while opportunities in product development and market expansion offer avenues for future growth.

Bristol-Myers reports robust Q1 earnings, eyes growth amid challenges

Bristol-Myers' Q1 2023 performance reflects strong sales growth and a focus on innovation, with significant progress in pipeline development and new product launches.
While facing challenges from generic competition and operational issues, the company is well-positioned to capitalize on industry advancements and strategic opportunities for growth.
By reaffirming guidance, emphasizing strategic alignment, and pursuing new therapies, Bristol-Myers demonstrates resilience and a commitment to long-term success in the pharmaceutical market.

Bristol-Myers reports robust Q2 sales and strategic growth initiatives

Bristol-Myers' Q2 performance showcased strong sales driven by new product growth and key product successes like Opdivo and Reblozyl.
While facing challenges with certain products and revenue guidance changes, the company remains confident in its financial commitments and growth outlook.
Opportunities lie in capacity ramp-up for key products, conversion strategies for patient assistance programs, and upcoming R&D insights.
Overall, Bristol-Myers' performance, strengths, and opportunities position the company for continued growth and success in the pharmaceutical market.

Bristol-Myers reports robust Q3 performance, eyes growth opportunities

Bristol-Myers Squibb's Q3 earnings call highlighted strong performance, strategic initiatives for growth, and confidence in future prospects. Despite challenges in product performance and reimbursement, the company is optimistic about market improvements and growth opportunities. Executives are focused on driving sustainable long-term growth and expanding their product portfolio.

Bristol-Myers reports robust Q4 earnings, eyes growth through strategic initiatives

Bristol-Myers' Q4 2023 showcased strong financial performance, strategic advancements, and a focus on growth drivers like Opdivo and new launches.
Despite challenges in negotiations and market dynamics, Bristol-Myers remains poised for growth through its robust product portfolio and business development strategies.
The company's emphasis on innovation, commercial execution, and clinical progress positions Bristol-Myers for sustained growth and market leadership in the pharmaceutical industry.

Bristol-Myers meets Q1 expectations, focuses on growth opportunities

Bristol-Myers Squibb's Q1 performance met expectations with strong sales growth driven by key brands and strategic acquisitions.
Despite challenges in operating expenses and interest costs impacting income, the focus on efficiency and cost savings remains a priority.
The company's strengths lie in robust sales growth of key brands, promising pipeline advancements, and strategic capital allocation plans.
Opportunities in expanding indications, new trials, and market launches position Bristol-Myers for long-term growth and competitive advantage.

Bristol-Myers reports strong Q2 performance, bullish on pipeline growth

Bristol-Myers (BMY) showcased a robust Q2 performance, emphasizing pipeline advancements and strategic capital allocation for growth and returns.
The company is confident in navigating pricing changes and improving access dynamics for key products, while focusing on transformative medicines and operational excellence.
With a positive outlook for the year, Bristol-Myers is poised to leverage opportunities in oncology, pipeline advancements, and expanding indications for key assets.

Bristol-Myers (BMY) reports strong Q3 sales and pipeline progress

Bristol-Myers Squibb (BMY) showcased robust performance with strong sales growth and positive clinical data for pipeline programs.
The company's strategic strengths lie in operational excellence, capital allocation, and commitment to sustainable growth and innovation.
Challenges include market dynamics, competition in heart failure drugs, and translating clinical data into successful drug programs.
Opportunities abound in the growing heart failure drugs market, upcoming trial data readouts, and continued focus on portfolio growth and operational efficiency.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

BMY lowered its full-year guidance due to currency headwinds. However, the portfolio performed as expected, and the company reported a number of important advances. Revlimid sales declined in line with expectations, and the company is strengthening its oncology portfolio with the recent acquisition of Turning Point Therapeutics and new indications for Opdualag.

Bristol-Myers Squibb: Q2 Earnings Performance Confirms My Bullish Stance

PRINCETON, N.J.--(BUSINESS WIRE)--BMS Provides Update on CheckMate -914 Trial Evaluating Opdivo Plus Yervoy as Adjuvant Treatment of Localized Renal Cell Carcinoma

Bristol Myers Squibb Provides Update on CheckMate -914 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) as Adjuvant Treatment of Localized Renal Cell Carcinoma

A looming patent cliff puts pressure on the company's newest products.

These New Blockbusters Could Fill Bristol-Myers Squibb's Revenue Gap

Bristol Myers Squibb Co said on Wednesday it had transferred its commercial operations in Russia to a third-party distributor and incurred $39 million in related costs.

Bristol Myers discloses $39 million in Russia exit costs

Bristol-Myers (BMY) earnings and sales beat estimates in the second quarter of 2022 on the back of Eliquis and Opdivo and a lesser decline in sales of Revlimid.

Bristol-Myers (BMY) Q2 Earnings, Sales Beat on Eliquis, Opdivo

Bristol-Myers Squibb Company (NYSE:BMY ) Q2 2022 Earnings Conference Call July 27, 2022 8:00 AM ET Company Participants Tim Power - Vice President, Investor Relations Giovanni Caforio - Board Chair & Chief Executive Officer David Elkins - Chief Financial Officer Chris Boerner - Chief Commercialization Officer Samit Hirawat - Chief Medical Officer & Head of Global Drug Development Conference Call Participants Andrew Baum - Citi Geoff Meacham - Bank of America Chris Schott - JPMorgan Steve Scala - Cowen Seamus Fernandez - Guggenheim Luisa Hector - Berenberg Tim Anderson - Wolfe Research Evan Seigerman - BMO Terence Flynn - Morgan Stanley Matthew Phipps - William Blair Carter Gould - Barclays Dane Leone - Raymond James Colin Bristow - UBS Mohit Bansal - Wells Fargo Robyn Karnauskas - Truist Securities Operator Good day and welcome to the Bristol-Myers Squibb 2022 Second Quarter Results Conference Call. Today's conference is being recorded.

Bristol-Myers Squibb Company (BMY) CEO Giovanni Caforio on Q2 2022 Results - Earnings Call Transcript

Bristol Myers Squibb expects a $10 billion or double-digit decline from its generics-facing products. BMY stock fell Wednesday.

The Generics Are Here: How Bristol Myers Squibb Expects Patent Losses To Hit In 2022

Shares of Bristol Myers Squibb BMY, +1.08% were down 2.5% in premarket trading on Wednesday after the company lowered guidance for earnings per share for the year. Bristol had earnings of $1.4 billion, or 66 cents per share, in the second quarter of 2022, compared with $1.0 billion, or 47 cents per share, in the same quarter a year ago.

Bristol Myers Squibb says Eliquis revenue jumped 16% in the second quarter

The company effectively lowered its sales guidance for 2022 slightly, saying it now expects $46 billion in sales for the year.

Bristol Myers Squibb Beats Earnings Estimates, but Shares Fall

Bristol Myers Squibb Co on Wednesday reported higher-than-expected second-quarter profit as a dropoff in sales of its blockbuster cancer drug Revlimid, which now faces generic competition, was not as steep as projected.

Revlimid sales drive higher-than-expected Bristol Myers results

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Reports Second Quarter Financial Results for 2022

Bristol Myers Squibb Reports Second Quarter Financial Results for 2022

Alkermes

Biogen

GlaxoSmithKline

Teva Pharmaceutical

Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA

Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More

Investors will likely focus on the demand for Eliquis and Opdivo along with incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q2 results. Operating expenses might have jumped.

Bristol-Myers (BMY) to Post Q2 Earnings: What is in the Cards?

AutoZone

Cisco Systems

KLA-Tencor

Kroger

McKesson

Moderna

Investors seeking shelter from the market selloff through 2022 can take a look at some of the best cash cow stocks to buy. The post 7 Best Cash Cow Stocks to Buy for Stable Returns appeared first on InvestorPlace.

7 Best Cash Cow Stocks to Buy for Stable Returns

AbbVie

Eli Lilly

Merck

The second-quarter earnings season is upon us, and the news coming out of several members of Big Pharma could potentially shake up their share prices. Beyond that, several unknowns could impact top-tier drug companies in the second half, including interest rates, federal drug pricing actions and scrutiny by the Federal Trade Commission.

2nd-Quarter Earnings Results Could Impact Drug Company Shares

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CHMP--BMS Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination, Opdualag ....

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for LAG-3-Blocking Antibody Combination Opdualag (nivolumab and relatlimab) for Treatment of Patients with Unresectable or Metastatic Melanoma

Amgen

These two dividend-paying pharmaceutical titans ought to keep crushing the broader markets for the foreseeable future.

2 Rock-Solid Dividend Stocks to Buy Right Now

The company is reshaping and expanding its oncology portfolio.

How These Acquisitions Are Changing the Outlook for Bristol Myers Squibb

Energy Transfer LP Unit

AT&T

A good strategy for this unprecedented backdrop may be to bunker down with steady dividend paying companies that are likely to trend higher as market conditions improve. Compared to what was available at the market peak, there are certainly some big dividend yields out there.

Get These 3 Juicy Dividend Yields While They Last

Gilead Sciences

ImmunityBio

Pfizer

Viatris

These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world.

7 Best Pharmaceutical Stocks to Buy Now

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Bristol Myers Squibb (BMY) Q2 Earnings Expected to Decline

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Launches Disability Diversity in Clinical Trials (DDiCT) Initiative to Improve Healthcare Outcomes for People with Disabilities

Bristol Myers Squibb Launches Disability Diversity in Clinical Trials (DDiCT) Initiative to Improve Healthcare Outcomes for People with Disabilities

Bristol Myers Squibb (NYSE: BMY) is scheduled to report its Q2 2022 results on Wednesday, July 27. We expect BMS to report revenue and earnings marginally above the consensus estimates.

What To Expect From Bristol Myers Squibb Stock After Q2 Results?

NEW YORK--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Announces Extension of Turning Point Tender Offer

Bristol Myers Squibb Announces Extension of Turning Point Tender Offer

Arhaus

EPR Properties

Kulicke & Soffa Industries

NVIDIA

Roku

Sonic Automotive

After the first two quarters of fiscal year 2022, who holds the top spot in the InvestorPlace Best Stocks for 2022 contest? Let's dive in.

News for Bristol-Myers Stock (BMY)